Skip to content

Cosentyx® (secukinumab) first interleukin-17A inhibitor PBS listed for non-radiographic axial spondyloarthritis (nr-axSpA)

By Gold Cross - April 1, 2021

Cosentyx
This article is only available to ITK members and is restricted for Pharmacists. Please or Register as a Pharmacist to read the content.
Share this article:
Article tags

Articles you might be interested in

Pharmacist Only
, , ,

Unstoppable and spared from impacts of Ex-Tropical Cyclone Alfred: APP2025 to go ahead as planned

Gold Cross | March 10, 2025

New STI impacts 1 in 3 women: landmark study reveals men are the missing link

Gold Cross | March 10, 2025
Pharmacist Only
, , ,

Two weeks until APP2025 brings the pharmacy industry together on the Gold Coast

Gold Cross | March 6, 2025
, , , ,

PATY 2025: Nominations now open!

Gold Cross | March 3, 2025
BD Rowa automation gives you back 6 hours in your day

Latest Posts

Pharmacist Only
Unstoppable and spared from impacts of Ex-Tropical Cyclone Alfred: APP2025 to go ahead as planned
Gold Cross | March 10, 2025
New STI impacts 1 in 3 women: landmark study reveals men are the missing link
Gold Cross | March 10, 2025
Pharmacist Only
Two weeks until APP2025 brings the pharmacy industry together on the Gold Coast
Gold Cross | March 6, 2025

Featured Posts

GOLD CROSS endorses Team Medical®
Gold Cross | February 18, 2025
College training supports new Australian Government women’s health initiative
Gold Cross | February 10, 2025
Professor Anna Peeters appointed VicHealth CEO
Gold Cross | February 4, 2025

Tags

Scroll To Top